After skepticism and tight vote at adcomm, FDA approves ChemoCentryx's rare disease drug
After a tight advisory committee vote back in May that tilted just slightly in favor of approving ChemoCentryx’s avacopan, the FDA has officially cleared the drug to treat a rare and serious disease known as anti-neutrophil cytoplasmic autoantibody (ANCA)-vasculitis.
The approval makes avacopan — now marketed as Tavneos — the first new drug in a decade for ANCA-associated vasculitis, according to trial investigator Peter Merkel.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.